argenx SE Stock

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles 11:35:02 2024-04-24 am EDT 5-day change 1st Jan Change
349.9 EUR +0.20% Intraday chart for argenx SE +2.91% +1.86%
Sales 2024 * 1.68B 1.8B Sales 2025 * 2.29B 2.45B Capitalization 20.78B 22.25B
Net income 2024 * -137M -147M Net income 2025 * 219M 234M EV / Sales 2024 * 11 x
Net cash position 2024 * 2.3B 2.47B Net cash position 2025 * 2.47B 2.65B EV / Sales 2025 * 8 x
P/E ratio 2024 *
-141 x
P/E ratio 2025 *
105 x
Employees 1,148
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.88%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease CI
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia MT
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
US Futures, European Stocks Rise After Fed Maintains Outlook DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading MT
Truist Securities Raises Price Target on Argenx to $440 From $370, Maintains Buy Rating MT
JMP Securities Adjusts Argenx's Price Target to $471 From $462, Keeps Market Outperform Rating MT
Baird Cuts Price Target on Argenx to $490 From $505, Maintains Outperform Rating MT
Global markets live: HP, Moncler, Snowflake, Salesforce, Duolingo... Our Logo
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
More news
1 day+0.20%
1 week+2.91%
Current month-4.43%
1 month-5.46%
3 months+3.89%
6 months-23.39%
Current year+1.86%
More quotes
1 week
335.10
Extreme 335.1
356.40
1 month
334.70
Extreme 334.7
378.30
Current year
322.50
Extreme 322.5
381.10
1 year
271.00
Extreme 271
494.10
3 years
201.40
Extreme 201.4
494.10
5 years
93.05
Extreme 93.05
494.10
10 years
6.23
Extreme 6.23
494.10
More quotes
Managers TitleAgeSince
Founder 52 07-12-31
Director of Finance/CFO 54 21-05-31
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Director/Board Member 71 17-04-25
Director/Board Member 74 15-05-12
Director/Board Member 63 16-04-27
More insiders
Date Price Change Volume
24-04-24 349.9 +0.20% 34,608
24-04-23 349.2 +3.59% 44,060
24-04-22 337.1 -0.06% 43,470
24-04-19 337.3 -1.37% 35,871
24-04-18 342 +0.59% 44,625

Real-time Euronext Bruxelles, April 24, 2024 at 11:35 am EDT

More quotes
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
349.9 EUR
Average target price
439.4 EUR
Spread / Average Target
+25.57%
Consensus